The evidence is balanced enough to avoid a defensive call, but not aligned enough for aggressive positioning.
56
technical evidence
out of 100
out of 100
Week Ending: 14 August 2026
Taiwan TW Healthcare Industry
Drug Manufacturers - General
For the week ending 14 August 2026, Drug Manufacturers - General advanced 7.59% with 3 advancing, 0 declining, and 0 unchanged constituents. The index is equal weighted and the constituent tape shows uncapped security returns.
Current architecture
Unresolved
The Activity Lines, Trend Line and price acceptance remain genuinely mixed.
56
technical evidence
Index1831.80
1 week7.59%
Breadth100%
Members3
Country
🇹🇼 Taiwan · TW
Sector
Healthcare
Universe
country-listed
Price basis
Adjusted weekly close
Trend architecture
Index, activity fan and structural anchors
Rolling 156-week evidence. Trend Signal points mark weeks when price, trend and the activity fan confirmed together.
Index Value
Trend Line
Fair Value
Activity Lines
Constructive architecture
Transitional architecture
Defensive architecture
Current architecture
Unresolved
10 completed weeks in this state
Trend acceptance
0.0%
Index versus Trend Line
Persistence
75%
Negative regime, shorter trend repairing
Participation
100%
3 advancing, 0 declining
Investor positioning lens
Is the evidence ready for capital?
A rules-based technical classification using trend, breadth, persistence, relative strength and path quality.
Evidence balance
Wait
Five-pillar map
Trend
34
Breadth
73
Persistence
50
Relative
72
Risk quality
66
What supports the view
- Participation is broad enough to support the index move.
- Relative performance is improving within its parent hierarchy.
What restrains conviction
- Index trend architecture has not delivered a durable upward expansion.
- Constituent persistence remains divided or predominantly negative.
- Stage 4 declining constituents exceed Stage 2 advancing constituents by 67 percentage points.
- Positive contribution is concentrated in a small leadership cohort.
This is a weekly research classification, not personal investment advice. Sentiment is reported as an independent confirmation layer and does not alter the technical score.
Trend state and durability
Architecture, persistence and constituent regimes
The index path is tested against the underlying security-level trend evidence.
The Activity Lines, Trend Line and price acceptance remain genuinely mixed.
State age10 weeks
Trend gateDown
Fan width1.98%
Fast versus slow change1.49 pts
Above 33%
Below 17%
Six completed weeks of price acceptance relative to the full Activity Line fan.
Index persistence
75% agreement
Negative regime, shorter trend repairing
The long trend remains negative, but shorter-horizon repair is now visible.
13-week
9.6%
26-week
-16.7%
39-week
-18.9%
52-week
-17.1%
Constituent trend persistence
Is the index move broadly durable?
Constituent persistence coverage is still building.
Custom stage map
100% coverage
Where constituents sit in the cycle
67%Stage 4
Stage 1 · Basing33%1 securities
Stage 2 · Advancing0%0 securities
Stage 3 · Distribution0%0 securities
Stage 4 · Declining67%2 securities
Re-acceleration watch0
Transition watch1
Relative strength leaders0%
Fair Value repairs1
Measured as of 14 Aug 2026. Stages summarize price, Activity Line architecture, Fair Value position and relative evidence.
Architecture breadth
56/100 mean confidence
How market energy is distributed
Architecture breadth shows the distribution of expanding, rotating, balancing and contracting securities. It is diagnostic context and is not added as a second vote in the positioning score.
Capital rotation
Performance relative to Healthcare
Relative index
13-week relative trend
Starting level
A rising relative line means this group is compounding faster than Healthcare. A falling line means capital has done better in the parent benchmark.
Relative index127.8
13-week trend118.2
4-week trend change2.55%
Weekly peer rank1 of 10
1 week
7.3 pts
relative
4 weeks
5.9 pts
relative
13 weeks
10.8 pts
relative
26 weeks
-7.3 pts
relative
52 weeks
-8.6 pts
relative
Market internals
Participation, dispersion and path risk
Equal-weight index evidence with constituent-level breadth and dispersion.
Breadth
Broad
Participation quality
100%
advanced
- Advancing
- 3
- Declining
- 0
- Unchanged
- 0
Risk and persistence
52-week lens
Path quality
Annualised weekly volatility23.0%
Drawdown from 52-week high-27.0%
Positive weeks, last 1354%
Current directional run2 weeks
Turnover versus 13-week norm169%
Breadth impulse58.3 pts
Cross-section
3 measured
Return distribution
Q1 1.2%
Median 1.9%
Q3 11.1%
Average winner7.6%
Average loser%
Dispersion9.0 pts
Top-five upside share100%
Top-five capital share100%
Capital data coverage100%
Dispersion describes how far constituent outcomes are spreading apart. Capital concentration is contextual only; the index itself is equal weighted.
Momentum cycle
30-week persistence
Positive readings show expansion. Negative readings show contraction.
Breadth cycle
Net participation
Advancers less decliners as a percentage of measured constituents.
News and narrative
Does company news confirm the market tape?
Sentiment evidence is still developing
Qualified company-level news coverage is not yet broad enough to influence the group view.
0 qualified records across 3 measured constituents.Leadership tape
Leaders, laggards and contribution shape
Latest completed week, ranked on uncapped constituent returns.
Constituent ledger
Industry constituents
All 3 measured constituents, ranked by latest weekly return.
Rank
Ticker
Company
Exchange
Market cap
Close
Index contribution
Return
The index uses capped equal-weight weekly constituent returns. The ledger shows uncapped security returns so outliers remain visible for research.